New Heart Failure Treatment Guidance Prioritizes Finerenone
The American College of Cardiology now lists finerenone as the preferred mineralocorticoid receptor antagonist.
Updated on Oct. 16, 2026 in Heart Disease
Live Poll
Do you trust your primary care provider to correctly identify and treat emerging chronic heart conditions?
The American College of Cardiology now identifies finerenone as the preferred mineralocorticoid receptor antagonist for treating heart failure with preserved ejection fraction. This update provides new guidance for clinicians managing the most common heart failure phenotype in the United States.
Why it matters
Heart failure with preserved ejection fraction is often unrecognized in primary care and rural settings. Updating treatment guidance helps clinicians better identify and manage this prevalent condition using therapies with more favorable adverse effect profiles.
The American College of Cardiology expert consensus decision pathway establishes finerenone as the preferred mineralocorticoid receptor antagonist. The medication is approved for patients with an estimated glomerular filtration rate as low as 25, compared to a floor of 30 for spironolactone.
The players
American College of Cardiology
A professional medical society that establishes evidence-based clinical practice guidelines for cardiovascular care.
The details
Finerenone functions as a nonsteroidal mineralocorticoid receptor antagonist, offering a distinct profile compared to traditional therapies. In chronic disease management, pharmacists are increasingly utilizing specific workflows to identify and optimize treatment for patients with heart failure with preserved ejection fraction. This approach aims to maximize guideline-directed medical therapy in both primary care and specialty settings.
Timeline
- 2026-10-16
The American College of Cardiology published the updated consensus decision pathway.
Health Landscape
Heart failure with preserved ejection fraction is the predominant heart failure phenotype in the United States. This update to the American College of Cardiology expert consensus decision pathway marks a shift in how clinicians prioritize medical therapies for this population.
If you are managed for heart failure, this updated guidance may influence the specific therapies your cardiologist selects. Discuss with your physician whether your current treatment plan aligns with the latest American College of Cardiology consensus and how it fits your specific kidney function profile.
The takeaway
The American College of Cardiology now prioritizes finerenone as the preferred mineralocorticoid receptor antagonist for heart failure management. Patients should consult their healthcare provider to discuss how current treatment guidelines apply to their individual heart health and kidney function.
Further reading
Learn more about the latest management strategies in the Heart Disease section.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Do you trust your primary care provider to correctly identify and treat emerging chronic heart conditions?
